Pharmafile Logo

dermatitis

- PMLiVE

AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

Around 700,000 people in the US are living with some form of the autoimmune disease

- PMLiVE

FDA grants fast track designation to Nektar’s rezpegaldesleukin in alopecia areata

Approximately 700,000 people in the US currently have some form of the autoimmune disease

- PMLiVE

NHS programme to give melanoma patients fast-track access to skin cancer vaccine

The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

regeneron headquarters

Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer

Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year

- PMLiVE

Merck shares positive ten-year results for Keytruda in advanced melanoma

More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year

- PMLiVE

FDA approves Sun Pharma’s oral JAK inhibitor Leqselvi to treat severe alopecia areata

The autoimmune disease currently affects around 700,000 people in the US

- PMLiVE

Moderna/Merck share positive three-year results for investigational skin cancer vaccine

More than 100,000 new cases of melanoma are expected to be diagnosed in the US in 2024

- PMLiVE

Almirall survey reveals limited knowledge of most common precancerous skin condition

An estimated 60% of squamous cell carcinoma cases, the second most common skin cancer, develop from AK lesions

- PMLiVE

Researchers develop microneedle patch to reverse hair loss caused by alopecia areata

The autoimmune skin condition currently affects more than six million people in the US

- PMLiVE

UK scientists discover two genes offering potential drug targets against skin cancer

The three major types of skin cancer are basal cell carcinoma, squamous cell carcinoma and melanoma

- PMLiVE

UK survey reveals two-thirds of vitiligo patients struggle with mental health

The Vitiligo Society has launched a campaign to address the lack of awareness and understanding surrounding the condition

- PMLiVE

UCB reveals positive phase 3 results for Bimzelx in moderate-to-severe plaque psoriasis

Affecting 90% of psoriasis patients, the chronic autoimmune disease causes red, itchy, scaly patches

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links